Efficacy and safety of MYL-1501D vs insulin glargine in patients with type 1 diabetes after 52 weeks: Results of the INSTRIDE 1 phase III study

2018 ◽  
Vol 20 (8) ◽  
pp. 1944-1950 ◽  
Author(s):  
Thomas C. Blevins ◽  
Abhijit Barve ◽  
Bin Sun ◽  
Michael Ankersen
Keyword(s):  
Type 1 Diabetes ◽  
Insulin Glargine ◽  
Phase Iii ◽  
Efficacy And Safety ◽  
Phase Iii Study

scholarly journals Low-Dose Otelixizumab Anti-CD3 Monoclonal Antibody DEFEND-1 Study: Results of the Randomized Phase III Study in Recent-Onset Human Type 1 Diabetes

Diabetes Care ◽  
2014 ◽  
Vol 37 (10) ◽  
pp. 2746-2754 ◽  
Author(s):  
Ronnie Aronson ◽  
Peter A. Gottlieb ◽  
Jens S. Christiansen ◽  
Thomas W. Donner ◽  
Emanuele Bosi ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Type 1 Diabetes ◽  
Low Dose ◽  
Phase Iii ◽  
Recent Onset ◽  
Human Type ◽  
Study Results ◽  
Phase Iii Study ◽  
Human Type 1 Diabetes
Sign in / Sign up

Export Citation Format

Share Document